Cadila Healthcare Ltd

Cadila Healthcare Ltd. manufactures, and markets healthcare solutions ranging from formulations, active
pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, animal healthcare to
cosmeceuticals. The Company's products are available in tablets, capsules, injections, liquids, dry syrups,
powders, granules, and ointments.

Cadila Healthcare Ltd is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat

state of western India. The company is one of the leading pharmaceutical companies in India, with INR
119.05 Billion revenue. It is a manufacturer of generic drugs.

Overview
Cadila Pharmaceuticals - Overview - The Care Continues

Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical companies in India. Over
the past six decades, we have been developing and manufacturing affordable medicines for patients
around the world.

Our innovation-led drug discovery processes ensure the health and well-being of people
around the world. Our enhanced investment in innovation and a strong track record in research and
development have produced medical miracles that have changed lives and made a profound impact on
real life.

Being a care-focused, research-driven company, we are committed to complying with the highest ethical
standard in clinical research and medical practice. We want to be valued not only for our pharmaceutical
products but also for the way we conduct our research and business activities.We lead our industry in
demonstrating the application of cutting-edge research to ethical business practices in producing the
alchemy of optimum health outcomes for all.

Vision
Our vision is to be a leading pharmaceutical company in India and to become a significant global player
by providing high quality, affordable and innovative solutions in medicine and treatment.

Mission
We will discover, develop and successfully market pharmaceutical products to prevent, diagnose,
alleviate and cure diseases.

We shall provide total customer satisfaction and achieve leadership in chosen markets, products and
services across the globe, through excellence in technology, based on world-class research and
development.We are responsible to the society. We shall be good corporate citizens and will be driven by
high ethical standards in our practices.

Heritage
Cadila cares about changing the trajectory of health for all humanity. For us, this is a calling and not just
a business. A calling, into which we have been steadily investing all our pioneering spirit, science, human
ingenuity and knowledge for the past decades. Throughout the company’s history, we’ve been guided by
the principles and personal example of our founder-chairman and his people-first approach.

Founder Chairman - Indravadan Ambalal Modi 1926-2012

Founder Chairman - Indravadan Ambalal Modi 1926-2012

Born on February 18, 1926, in a small village in Bharuch, Indravadan Ambalal Modi was on a mission to
attain Swaraj (self-dependence) in healthcare for India. His compassion for the poor ignited his dream to
make medicines affordable for all.

First Employee - Shilaben Indravadan Modi 1931-2016

First Employee - Shilaben Indravadan Modi 1931-2016

Shilaben Modi, the first employee of Cadila Laboratories, was a perennial source of inspiration to her
husband, I. A.Modi. Her concern for people's well-being led to the manufacture of Cadila Gripe, the first
indigenously produced gripe water in India.

Self-Made Entrepreneur1951

I.A. Modi was not deterred by his resource constraints, he would ride over 40 km daily on his bicycle to
visit doctors. At the age of 25, he was a producer, manager, administrator, accountant and delivery man –
all rolled into one.

Cadila Laboratories 1952

I.A. Modi's first step in the pharmaceutical world began with the establishment of Cadila Laboratories on
March 13, 1952. One of the company's first products, Livirubra was a vitamin supplement in liquid form.

First Factory 1967

With the foundation of its first factory premises at Ghodasar, Cadila began a journey of unprecedented
growth.

Medicine Man of India 1970

Committed to nation building, Shri I A Modi, worked tirelessly to coagulate the Indian pharmaceutical
industry by championing the Indian Patents Act, 1970 and formulating the 1986 Drug Policy of the Govt.
of India. His efforts to make necessary drugs available to the marginalized earned him the title of
'Medicine Man of India'.

Beyond business 1985

Long before Corporate Social Resposibility had become a business mandate, Shri I A Modi instituted
Kaka-Ba Hospital as a homage to his cousin Budh, who died of typhoid due to lack of medical facilities.
This multi-speciality charity hospital provides free healthcare to thousands of impoverished lives.

A New Beginning 1995

In 1995, Cadila Laboratories was restructured and rechristened as Cadila Pharmaceuticals.

The Growth Story 1999-2006

Cadila’s manufacturing capabilities grew from strength to strength with its state-of-the-art facilities.

Bulk drug manufacturing facility at Dholka, Ahmedabad

Formulation facility at Samba, Jammu API facility at Ankleshwar, Ahmedabad

Africa - Our Second Home 2004

Cadila established Ethiopia’s first WHO-cGMP compliant plant in Addis Ababa. It soon became an
epicentre of multi-fold growth and development for Africa through enhanced investments.

Innovative Miracles 2004

Cadila developed pioneering first-in-the-world innovations for the treatment of cardiovascular diseases,
lung cancer and tuberculosis.Polycap, Mycidac-C, Risorine, Rabeloc IV and Immuvac

More than a Pharma Company 2005

Spreading the message of universal wellness, Cadila has expanded by diversifying into a host of
industries.

1982 Karnavati Engineering Ltd. - Pharmaceutical Machinery

1983 Vetnova - Veterinary solutions

1986 IRM Ltd. - Travel and hospitality

1992 CadiAgro - Tissue Culture

2009 CPL Biologicals Pvt. Ltd. - Vaccines and diagnostics

CURRENT PRICE
CDH:IN259.00INR-1.05-0.40%

AS OF 12:31 AM EST 03/02/2020

SECTOR
Health Care

INDUSTRY

Biotech & Pharma

SUB-INDUSTRY

Generic Pharma

FOUNDED

05/15/1995

ADDRESS
Zydus Tower Satellite Cross Roads Ahmedabad, 380 015 India

PHONE
91-79-2686-8100

WEBSITE
www.zyduscadila.com

Values and Purpose

Authenticity

Being Trustworthy & Genuine

Responsibility

Being Accountable & Taking Charge

Integrity

Being Reliable & Adhering to Principles

Our Purpose
Our purpose underpins everything we do. It gives us the motivation to make a deep impact on society
through the work we do. It helps us deliver startling benefits to patients and create value for all our
shareholders. This sets a meaningful context for all working in Cadila thereby making them ambassadors
of global wellness.

In the course of our activities and the pursuit of our goals, we make sure that the end beneficiaries of
our work are patients

We apply science to cause

In the course of our activities and the pursuit of our goals, we make sure that the end beneficiaries of
our work are patients. We exist to ease out their suffering, cure what can be cured, manage their
diseases and improve their quality of life.

With the motive to make medicines accessible to all Indians at an affordable cost, Cadila plays a crucial
role by formulating drugs in India.

We deliver affordable medicines

With the motive to make medicines accessible to all Indians at an affordable cost, Cadila plays a crucial
role by formulating drugs in India. This mission has grown wings and we are today catering to the
healthcare needs of over 85 countries worldwide.

All our research and development activities are focused on finding cures to complex diseases.

We research to defeat diseases

All our research and development activities are focused on finding cures to complex diseases. This goal is
integral to our drive for achieving success in our research initiatives.

In all that we do, our values guide our decision-making, define our beliefs and foster a strong
'intrapreneurial' culture at Cadila.

corporate governance
A Company With a Conscience

Commitment to Care
At Cadila, our actions speak to the world how we realise our commitment to care. We accomplish this by
ardently pursuing quality and in process, witnessing amazing stories of commitment worth sharing with
the world. By publishing these stories, we want people to look at how the future can be better by their
commitment to care.
Healthcare
Let's swap notes and experiences that spread the healing word around

Innovation

Keeping tabs on new and amazing breakthroughs in medical management

Employees

The complete lowdown on our employee's stories contributing to our legacy of care

Humanity

Tracing Cadila's history of care through interesting CSR stories

Trending Stories

Stories Worth Sharing

A Safe Infrastructure Makes an Employee’s Experience Richer

A Safe Infrastructure M...

17th Feb, 2020

Employees

Mr Sekar Manickam, Cadila Pharmaceuticals, talks about ...

Practicing Sustainability - The Priority for the Pharma Industry Today

Practicing Sustainabili...

11th Feb, 2020

Healthcare

Biswajit Mitra of Cadila Pharma talks about how the imp…

Each day, a new learning - Mona Gogia on Cadila’s learning ecosystem 22nd Jan, 2020

Employees

Cadila’s vision is to make affordable and quality medicines for common man Cadila’s vision is to…

9th Jan, 2020

Innovation
In an interview with Pharma Bio World, Cadila's interna...

The Art of Learning in the Corporate World

The Art of Learning in ...

12th Dec, 2019

Innovation

Dr Sunil Singh, CHRO-Cadila Pharma, talks about how the...

Don’t care about the biases: Smita Holey

Don’t care about the ...

15th Nov, 2019

Employees

Read the story about Smita Holey, how she braved all od...

APIs
It's all about quality, from source to resource

Cadila is one of the top Active Pharmaceuticals Ingredient (API) manufacturing companies in the world,
and one of the few pharmaceutical companies that is vertically-integrated with a very strong and
independent positioning in both the API and the Formulations markets.

Spread over 80,000 sq. meter area, our API manufacturing facility at Ankleshwar, Gujarat is globally
accredited by US FDA, ISO 9001:2008, COFEPRIS, PMDA Japan, EDQM Europe, TGA Australia, WHO
Geneva, etc. Recognized as the world’s top API supplier, our cost competitiveness and quality obsession
has been a critical influence in driving our profitability and growth in the formulations market as well.

Our diversified portfolio in APIs caters to over 90 countries. At present, we offer over 38 APIs and
intermediates across various therapeutic categories – respiratory, diabetology, gastroenterology, pain
management (antimigraine), orthopedics and many more. With 31 Drug Master Files and 12 Certificates
of Suitability and many more in the pipeline, we are confident of building an unmatched API portfolio in
the world.

Therapeutic Category
Therapeutic Category API Name

Anti-depressant Atomoxetine HCL

Anti-depressant Fluoxetine HCL

Anti-depressant Venlafaxine HCL

Anti-diabetic Glibenclamide/Glyburide

Anti-diabetic Nateglinide HCL

Anti-emetic Ondansetron HCL

Anti-histaminic Desloratadine

Anti-histaminic Loratadine

Anti-histaminic Rupatadine Fumarate

Anti-hyperlipidemia Atorvastatine Calcium Form-1

Anti-hypertensive Amlodipine Base

Anti-hypertensive Irbesartan

Anti-hypertensive Nebivolol HCL

Anti-hypertensive Amlodipine Besylate

Anti-hypertensive Phthaloyl Amlodipine

Anti-inflammatory Celecoxib

Anti-osteoporotic Alendronate Sodium

Anti-psychotic Aripiprazole Type 1

Anti-psychotic Olanzapine Form-I & II

Anti-thrombotic Cilostazol

Anti-tuberculous Ethambutol HCL

Cardiotonic Bosentan Monohydrate

Cardiovascular Carvedilol

Disinfectant Chlorhexidine Base

Disinfectant Chlorhexidine Gluconate 20%

Disinfectant Chlorhexidine HCL

Erectile dysfunction Sildenafil Citrate

At Cadila, we take our partners very seriously. We deliver high-quality generic products to diverse
markets quickly and cost-effectively. Working in close collaboration with our clients, Cadila is able to offer
a superior range of products, besides end-to-end support, throughout the production process.

We are able to do this by assigning a dedicated, fully-responsive resource unit to each client. This unit
provides all kinds of research and logistical support, as well as quality assurance and marketing-related
assistance to our clients.

Formulations
Our extensive range of finished dosage formulations covers every aspect of human life. Our basket of
formulations contains more than 850 products in several forms belonging to 45 therapeutic segments
and 12 specialties including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and
antibiotics, respiratory agents, antidiabetics, immunologicals and oncology. Our formulation business
fulfils the need for domestic, regulated, and rest of the world markets.

Our globally accredited, state-of-the-art manufacturing facilities in Dholka (Gujarat), Samba (Jammu and
Kashmir) and Addis Ababa (Ethiopia) produce almost all dosage forms including sterile as well as non-
sterile products.

Formulations-IndiaFormulations-International

Generic Name

Product Name Generic Name Pack Style Dosage Form Division

ABRETONE 250MG TAB-120 TAB Abiraterone acetate 250mg 1X120 T Tablet Oncocare

ACENEXT MR TAB Aceclofenac 100mg +

Paracetamol 500mg +

Chlorzoxazone 250mg 20X10T Tablet Newgen

ACENEXT P TAB Aceclofenac Bp 100 mg +

Paracetamol 32 mg 30X10 T Tablet Newgen

ACENEXT PLUS TAB Aceclofenac Bp 100 mg +

Paracetamol 325 mg 10X10 T Tablet Newgen

ACENEXT SP TAB Paracetamol IP 325 mg +

Aceclofenac 100 mg +

Serratiopeptidase 15 mg 20X10 T Tablet Newgen

ACENEXT TAB Aceclofenac I.P. 100 mg 20X10 T Tablet Newgen

ACIBAN 40MG TABS Pantoprazole sodium sesquihydrate Eq

to,Pantoprazole 40mg 10X10 T Tablet Magna Star

ALBENDAZOLE TAB Albendazole I.P. 400mg ) 100X1T Tablet Newgen

ALCOHOLIC RUB HAND DISINFECTANT 3235 - 500 ML BOT Bottle

ALERTRIZ 5MG TAB Levocetirizine Dihydrochloride I.P 30X10 T Tablet Newgen

Contract Research Operation

Walking the Extra Mile for You

Ready for a CRO that values performance over promises? We accept the challenge

Cadila has its own Contract Research Operation (CRO) business unit at Dholka in Ahmedabad, Gujarat.
The CRO offers a series of pre-clinical and clinical trials for drug development that cover over 45
therapeutic categories, namely cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives,

antibiotics, respiratory, anti-diabetics, and immunologicals. It is a one-stop destination for managing all
contract research activities, ranging from pre-clinical, BA-BE to Phase II to Phase IV trials.

Our CRO is a Center of Excellence (CoE) where we accelerate our clients’ drug development process with
our in-house talent and world-class resources. Till date, we have conducted over 1000 pre-clinical
studies, 390 BA-BE studies and 28 clinical trials.

Collaborate with us
When you partner with Cadila, you immediately gain competitive advantage over other CROs in terms of
increased patient enrolment, retention and compliance with the laid-down law and procedures.

By choosing to employ our Clinical Research service in your next Request For Proposal (RFP), you will
gain instant access to operational efficiencies and quality benchmarks that you would not have
subscribed to before. Our years of expertise in this area will effectively complement your outsourced
vendor framework. The outcome would be on-time, within-budget delivery.

Significant patient enrolment

Assurance of maximum patient comfort, safety, satisfaction, and convenience

Access to a heterogeneous, widely diverse, genetic pool of subjects

Access to enhanced geographic reach of sites

Assurance of full compliance with protocol requirements Complete, accurate, timely and compliant
documentationA single contract, meaning consolidated monthly invoicesSeamless integration into the
study execution

Cadila PharmaceuticalsToggle navigation

Alliances

Collaboration that brings change

We collaborate with reputed organisations with the vision to bring revolution in the healthcare sector.
Their firm belief in Cadila’s philosophy has helped us together create a valuable impact in the society.

Apollo Hospitals
In 2006, Cadila Pharmaceuticals entered into a joint venture with Apollo Hospitals Group to manage
Apollo Hospitals, Ahmedabad. Over the last decade, it has been recognized as a centre of excellence and
has emerged as a trusted destination for the patients in the region.

Stemcyte

In 2008, Cadila Pharmaceuticals formed a JV with StemCyte Inc. USA, organization dedicated to the
collection, processing, testing and storage of both – private and public umbilical cord blood units and its
therapeutic applications.

Novavax

In 2009, Cadila Pharmaceuticals acquired a significant stake in Novavax Inc., USA, a clinical-stage
biopharmaceutical company to form a joint venture, CPL Biologicals, which develops and produces
vaccines based on virus-like-particle (VLP) methodology.

Lipidor

Under a research collaboration agreement with Lipdor, Cadila Pharmaceuticals has initiated a phase 3
clinical trial for the development of differentiated Calcipotrial formulation ( Spray) for the treatment of
Psoriasis.

Aplagon

In 2017, Cadila Pharmaceuticals entered into a collaboration with Aplagon Oy, Finland for development
and commercialization of heparin proteoglycan mimetic for use in certain vascular surgeries.

Contact ADR Reporting Privacy Policy Drug Counterfeiting

IRM Group Companies

IRM has unmatched capabilities across Agriculture, Veterinary, Pharma Machinery Manufacturing,
Travel, Forex, Aviation and Hospitality Industry, and maintains a leadership in all its major lines of
businesses.

Living Our Passion

A nationalist at heart, I.A. Modi was determined from the start to spread the message of universal
wellness and led the expansion of Cadila by diversifying it into a plethora of industries.

With a strong customer focused approach and a continuous quest for world-class quality, IRM has
unmatched capabilities across Agriculture, Veterinary, Pharma Machinery Manufacturing, Travel, Forex,
Aviation and Hospitality Industry, and maintains a leadership in all its major lines of businesses.

Visit www.irmgroup.co.in to know more.

Expanding Our Vision

For the Betterment of Society Cadagro

CADAgro is a diversified Agri-business company providing Tissue Culture, Potato Tubers and Organic Agro
Inputs like Bio-Fertilizers, Bio-Pesticides, Bio- Fungicides and Botanicals. Founded in 1992, the company's
mission is to make Indian farming economically viable, safe and sustainable. CADAgro is one of the first
companies in India to bring the tissue culture technology. Our research focused division, the R&D
department is a Centre of Excellence in Tissue Culture and Bio products dedicated to produce novel
solutions for superior customer satisfaction.

CPL Vetnova

CPL VetNova division provides innovative solutions for comprehensive livestock care viz. Veterinary
Pharmaceuticals, Nutraceuticals, and Neutro-Pharmaceuticals for cattle and poultry. Established in 1972,
this veterinary division offers a range of veterinary products for reproductive care, hepatic care, digestive
care, mammary care, derma care, productivity enhancement and nutritional requirement.

Karnavati Engineering

Karnavati Engineering was established in 1981 to supply differentiated and customized machinery to the
pharmaceutical industry through innovative thinking and quality assurance. The company manufactures
tablet compression, capsule filling machines, R&D instruments, punches and dies and granulation
equipment. The division’s manufacturing facility in Kadi, Gujarat confirms to the most stringent global
cGMP standards. The company’s core strength lies in customizing and configuring machinery depending
on the end product.
Green Channel Travel Services

Incorporated in 1986, Green Channel Travel Services is India’s largest retail FOREX and Travel company
having 14 corporate branches all across the country. GCTS offers a broad spectrum of services that
include leisure and corporate travel, foreign exchange, insurance and related business to large
corporates, NGOs and educational institutions.

Green Channel Air

Green Channel Air is a division providing charter services. The company’s CITATION CESSNA MUSTANG
510 is one of a kind jet and is a superior model in the Very Light Jets (VLJs) category which provides
Emergency Medical Organ Transportation. With over 400 aircrafts in operation around the globe, the
Mustang is GC Air’s most popular aircraft for short duration flights.

Facility Management Services

Facility Management Services (FMS Division) is a hospitality vertical providing guest house facilities and
bakery products. Founded for serving superior comfort for travelers all across India, this division runs by
the traditional Indian ethos of Atithi Devo Bhava.

Rousdonmullai Tea Estate

The Estate has a state-of-the-art facility for manufacturer of quality tea. The present capacity for
production is 1.5 Million kilo per annum. The division having one more factory in Devala (outside Estate)
having capacity for production of 1.5 million kg per annum.

World’s First Innovation

Leading the Wellness Revolution

In each of our endeavours, we strive to serve mankind and aim for the well-being of all. With this vision
in mind, we formulate drugs that effectively treat the disease and foster healthy families, cities,
countries, and the world at large. Our unique formulations are accepted by various countries, and they
have successfully countered the illness and enhanced the health of their people.

Rabeprazole sodium for intravenous administration to treat various diseases like GERD, Upper GI Bleed,
APD etc. It has rapid onset of action with sustained and long term lowering of gastric Ph. Rabeloc is
freely compatible with commonly used IV fluids and diluents and should be given IV. It is very much safe
in special population like elderly/liver/kidney dysfunction patients as having the lowest drug interactions
because of non-enzymatic pathways for metabolism. Rabeloc is available as in vial.

The Global Pharmaceuticals Market

The global sales of prescription pharmaceutical drugs is expected to have grown by only 1% in 2017.
During the period 2011 to 2017 too, the global prescription drug sales are estimated to have grown at a
CAGR of only about 1%. Large sized pharmaceutical brands losing patent protection and continuous
pricing pressure on generic drugs fuelled by competition and government actions in the large markets

have been the key factors behind such low growth over the last few years. Drug affordability and
accessibility continue to create downward pressure on the market with payers across the globe
continuously making all possible attempts to limit prescribing options to drugs.

About the Company

Cadila Healthcare Ltd. is one of the leading pharmaceutical companies in India with presence across the
pharmaceutical value chain of research, development, manufacturing, marketing and selling of finished
dosage human formulations (generics, branded generics and specialty formulations, including biosimilars
and vaccines), active pharmaceutical ingredients (‘APIs’), animal healthcare products and consumer
wellness products. The Company has a global presence and sells its products in the UnitedStates, India,
Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The
Companyhas a pool of modern, cost efficient and regulatory compliantmanufacturing facilities which
ensures continuous supply ofhigh-quality products at the most competitive prices to its customers across
the globe. The Company is also engaged in research and development activities focused across the value
chain of API process development, generics development forsimple as well as differentiated dosage
forms like modified release oral solids, transdermals, topicals and nasals, biologics, vaccines, and New
Chemical Entities (‘NCE’).

Year 2017-18 for the Company

It was a very successful year for the Company’s largest business viz. the US formulations business. During
the year, the Company’s largest formulations manufacturing facility located at Moraiya, started receiving
approvals for new products for the US market from USFDA, post successful resolution of the warning
letter. The Company received approval for 77 new products (including eight tentative approvals) for the
US market during the year, which was the highest number of approvals received in a single financial year.
Launch of mesalamine 1.2 g DR tablets (generic version of Lialda®) in July 2017 with 180 days exclusivity
was the Company’s first large First to File (FTF) opportunity. The launch of Oseltamivir Powder for oral
suspension 6 mg/ml (generic version of Tamiflu®) coupled with the strong flu season also boosted the
performance of the US business. During the year, the Company moved a step further in its endeavour to
build the specialty pipeline in the US as the USFDA granted approval for pitavastatin magnesium tablets,
the first product filed through the 505(b)(2) route, which was recently launched in the US as
ZypitamagTM.

On the regulatory front, both the Moraiya and the Topical formulations facilities successfully completed
the USFDA inspections twice without any observations. The API facility at Dabhasa also successfully
completed the USFDA inspection with no observations. The year turned out to be a challenging one for
the Company’s second largest business viz. the India formulations business on account of the nationwide
roll out of the Goods and Services Tax (GST) Act with effect from July 1, 2017, resulting in de-stocking of
inventories by distributors, thereby impacting the performance of the first quarter adversely.

Global Generics Business

The US is the world’s largest pharmaceutical market, where unbranded generics have reached the
highest prescription share of over 85% of the total market, with annual sales value of over USD 90 billion
(Source: Industry Estimates). 2017 was a record year for ANDA approvals by USFDA, with over 1000
approvals. While unbranded generic prescription volume continues to have a steady demand in the US,
the generic drugs market is facing price deflation, decreased value growth and concentrated
buyingpower, with the top 3 generic drugs purchasers holding over 90% share.

World’s First Innovation

Leading the Wellness Revolution In each of our endeavours, we strive to serve mankind and aim for the
well-being of all. With this vision in mind, we formulate drugs that effectively treat the disease and foster
healthy families, cities, countries, and the world at large. Our unique formulations are accepted by
various countries, and they have successfully countered the illness and enhanced the health of their
people.

A product that has revolutionized the treatment for TB by reducing the dose of Rifampicin as it contains
Piperine, a potent bioavailability enhancer. By reducing the dose to half, patients will have lesser
gastrointestinal adverse effects and better tolerability. Improved patient compliance leads to better cure
rate and lesser treatment failure while maintaining therapeutic levels of Rifampicin. It is available in the
form of hard gelatin capsule.

Rabeprazole sodium for intravenous administration to treat various diseases like GERD, Upper GI Bleed,
APD etc. It has rapid onset of action with sustained and long term lowering of gastric Ph. Rabeloc is
freely compatible with commonly used IV fluids and diluents and should be given IV. It is very much safe
in special population like elderly/liver/kidney dysfunction patients as having the lowest drug interactions
because of non-enzymatic pathways for metabolism. Rabeloc is available as in viaR&D ChroniclesOur
R&D Process imageRigorous Research Leading to SuccessOur dedicated R&D department comprising 300
scientists, work day and night applying science to the cause of finding cures. They collaborate closely
with business development associates to come up with breakthrough ideas for addressing patient needs
and find synergies that cut-across therapeutic domains. The main focus is to develop affordable novel
products with the help of niche technologies.
We take immense pride in the strong intellectual capital of our staff and the many years of experience
that they bring to Cadila’s labs in chemistry, analytical techniques, dosage forms, new formulations,
preclinical research, clinical research or even patent law.

Research Areas
1. Formulation Development

2. Herbal Product Development

3. API solutions

4. Pre-Clinical and Clinical Research

5. Biotechnology

API Development
Our chemical development scientists are equipped with the skills to synthesize APIs of the highest
quality in a cost-optimized, eco-friendly manner. From the development of non-infringing products to
multi-scale synthesis spanning from gram to kilo level, our team delivers at every request. The focus
areas of research for development include gastroenterology, cardiovascular system, central nervous
system, antiemetic and anti-allergic.

Core Offerings

We take our partnerships with our clients very seriously. We leave no stone unturned in delivering highly
effective generic and innovative products quickly and efficiently. Whether it is a technical, regulatory,
logistical, marketing, or an IP issue, we are here to support you.

• Process Chemistry

• Analytical Development

• Process Engineering and scale-up

• Regulatory Affairs

• Intellectual Property

Our Development Process

Cadila believes that formulation is a data-driven science that must adhere to a laid-down, quality-vetted
process. After carefully analysing and understanding a client's specific needs, we create a target product
profile (TPP) that is clearly and unambiguously defined before developing any product algorithm.In
addition, our strategies for formulations development ensure compliance with stringent international
quality norms and regulatory practices. Our Quality by Design (QBD) approach uses time-tested
Modelling and Design of Experiments (DoE) approach to deliver a robust regulatory package of a
product.

Life at Cadila
Right Environment for Growth and Happiness

At Cadila Pharma, we aim to maintain a conducive environment that nurtures talent and facilitates
growth. Our core developmental strategy is to keep our employees healthy and happy, always.Cadila
Pharma’s ‘people strategy‘ contributes to the success of the business and is also a ‘feel-good’ factor for
our employees. We endeavor to provide a healthy work-life balance through many vibrant sports,
cultural and social development activities. These extra-curricular activities help our people loosen up and
have fun.

Growth & Development

Cadila University is an integrated development platform designed to tap the highest potential in our
employees through learning and development initiatives. From our medical representative to our senior
leaders, everyone is provided a customized program that covers the entire employee career path.

Media
Cadila Pharmaceuticals and Kaka-Ba trust has always been working for the society. They have been
organizing health camps, planting trees in and around Ahmedabad including primary schools where
students were encouraged to be a responsible citizen. Kaka-Ba trust has particularly been promoting the
education of young students by taking initiatives such as providing green boards to govt. schools, mid-
day meals and constructing class rooms for the schools.

Cadila Pharmaceuticals Ltd’s, innovation-led drug discovery processes ensures the health and well-being
of people around the world. Being a care-focused, research-driven company, they are committed to
complying with the highest ethical standard in clinical research and medical practice.

February 20, 2020: Cadila Pharmaceuticals on Wednesday received its Great Place To Work Certification
in the category of large organizations from February 2020 to January 2021.

Great Place to Work Certification Program is just the first step for Cadila in its journey to build a High-
Trust, High-Performance Culture. The team is now working hard to improve on the categories where
Cadila got average score to build an ideal workplace.
Cadila Pharma’s innovation-led drug discovery processes ensure health and well-being of people around
the world. Being a care-focused, research-driven company, it is committed to complying with the highest
ethical standards in clinical research and medical practice

Therapies
Gastroenterology
First-rate Formulations to Address Gastroenterology

Cadila specializes in providing time-tested therapeutic solutions that cover the vast spectrum of sub-
specialties of gastroenterology. Our wide portfolio of drugs is designed to build gut health and provide
superior relief.

Acid Peptic Disorders (APD)

Cadila has a solid presence in the APD segment with various classes of drugs such as Antacids, D2
Receptor Blockers, Proton Pump Inhibitors and Histamine 2 Receptor Blockers. We are the first in the
world to launch a novel intravenous formulation of Rabeprazole in the market, Rabeloc IV. Rabeloc IV is
an intravenous Proton Pumps Inhibitor (PPI) which rapidly reduces gastric acid production and
intragastric pH and is used during upper gastrointestinal bleeding. It has also been used to manage
various conditions like severe refractory gastro-oesophagus reflux disease, stress-induced mucosal injury,
acute upper non-variceal bleed, upper gastrointestinal bleeding. Other well-known brands of Cadila in
the APD segment are Aciloc (Ranitidine), Aciloc S (Magaldrate + Simethicone + Oxetacaine), Aciloc RD
(Omeprazole + Domperidone), Rabeloc (Rabeprazole), Rabeloc Plus (Rabeprazole + Levosulpiride),
Rabeloc RD (Rabeprazole + Domperidone) and Rithem (Levosulpiride).

Inflammatory Bowel Diseases (IBD)

Cadila provides several drugs for the treatment of IBD such as Mosart OD and Granules (Mesalazine),
LMX Forte (Amoxycillin + Clavulanic Acid), Faxicad (Rifaximin), Trigan D (Dicyclomine), Valdone
(Curcumin), Cadbios (Pre-probiotics) and Cadbios Forte.

Irritable Bowel Diseases (IBS)

Our core drugs for treating IBS include O Duo (Ofloxacin-Ornidazole) and Cibis (Dicyclomine + Clidinium
bromide + Chlordiazepoxide).

Constipation
Cadila offers a wide range of drugs for treating constipation. They include Cadilose Enema (Lactulose),
Cadilose Green (Lactitol + Ispaghula), Pegwash (Polyethylene Glycol), Pegmini (Powder for Oral Solution)
and Laxia (Liquid Paraffin).

Fatty Liver Disease

Cadila offers ursodeoxycholic acid (Ursocad), statins (Caditor, Rosuflo, Rosuflo F and Rosmi) and
antioxidants (Cadihep) for the treatment of fatty liver disease.

Cardiology

Cadila provides an extensive range of products for the prevention and treatment of cardiovascular
diseases (CVD). Our first-in-the-world innovation, Polycap launched in 2009 is a polypill for primary
prevention of cardiovascular events and stroke; it is designed to reduce patient pill burden and to
improve patient compliance. Our cardiology range also caters to hypertension which is a major
contributor to premature deaths related to CVD.

Gynaecology

Cadila has established its presence in the segments of gynaecology and obstetrics with its
comprehensive range comprising of infertility treatment, iron supplement for anaemia, hormones and
pregnancy care.

Key Brands

• HeamUp for iron-deficiency anaemia

• Myonext for PCOS

• Dynocad for endometriosis

• New Alene for male infertility

• Calnew-HD for nutrition

• Algest for female infertility

• Folnew for folate deficiency anaemia

Cadila PharmaceuticalsToggle navigation

Diabetology

For decades, Cadila has a strong presence in diabetic therapy with the easy availability of insulin and oral
hypoglycemic drugs such as teneligliptin, metformin, gliclazide, glimepiride, etc.

Key Brands
• Humstard

• Tenali M

• Glista M

• Glyloc

Oncocare Mission

Redefining the treatment paradigm to eliminate cancer as a cause of death and to provide high-quality
medicine at low cost which can is affordable to the last man of society.At Cadila, we aim to redefine the
treatment paradigm of cancer to eliminate it as a cause of death by providing high-quality medicine at
low cost which is affordable for all.We are committed to develop breakthrough biomedical innovations to
help extend and improve the lives of people suffering of cancer worldwide. With a combination-focused
pipeline that exploits the power of science, we aspire to address unmet clinical needs in a host of
cancers.

Key brands

• Bortecad

• Cadilap

• Lagipeg

• Paclicad

Vijay KUMAR17th July, 2019

Best company

montu sharma29th June, 2019

Best company

Keshav dutt19th July, 2018

Hard working staff and excellent working capabilities

Suresh kumar28th July, 2017

I indeed very happy to say that I got the opportunity to share my views here.. Thank you so much.. And its my

wish to work with your company.. It will be great platform and opportunity for me .

Chauhan11th July, 2017

Best company
vinoddhiman22nd January, 2015
100% reputation in the market.

Saaynee Patra17th July, 2019

Excellent

chandra kant13th April, 2019

Very Good

Load More Reviews..

Frequently Asked Question
1. What are the various mode of payment accepted here ?
You can make payment Via Cash.
2. Which is the nearest landmark ?
You can easily locate the establishment as it is in close proxomity to Near Bus Stand, Swaraj Majra, Juddi
Kalan
3. What are its hours of operation ?
The establishment is functional on
Monday:- 9:00 Am - 6:00 Pm
Tuesday:- 9:00 Am - 6:00 Pm
Wednesday:- 9:00 Am - 6:00 Pm
Thursday:- 9:00 Am - 6:00 Pm
Friday:- 9:00 Am - 6:00 Pm
Saturday:- 9:00 Am - 6:00 Pm
Sunday:- Closed

Most Searched
Computer Dealers Cake Shops Readymade Garment Retailers Car Repair & Services Hospitals General Physician
DoctorsCourier Services-DTDC Placement Services (Candidate) Computer Training
Institutes Eye Hospitals